Cell and gene therapies: bringing innovation to market
With the potential of 40+ groundbreaking cell and gene therapy products FDA-approved by 2024, manufacturers are looking for innovative ways to successfully bring these therapies to market.
Join AmerisourceBergen experts as they discuss commercialization considerations that manufacturers should know. In this webinar, you’ll learn more about:
The importance of patient connection through an integrated supply chain
Key models for cell and gene therapy reimbursement strategies
Matching distribution models with therapy requirements
Advancing cell and gene therapies
When healthcare advances, so must the processes to connect patients to the therapies they need. And because a rapidly changing cell and gene therapy industry requires an equally innovative partner, AmerisourceBergen is committed to delivering solutions that enable this connection.